Know Cancer

forgot password

A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer

Phase 2
18 Years
Not Enrolling
Hormone Refractory Prostate Cancer

Thank you

Trial Information

A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer

Inclusion Criteria


1. Signed & dated written informed consent obtained from subject in accordance w/local

2. Histologically confirmed conventional and/or mucinous adenocarcinoma of the prostate.
If histological confirmation is not available, cytological confirmation will be
permitted in lieu.

3. Must meet one of following 3 criteria for progressive disease following androgen

A. Subjects w/nodal or visceral metastases:

Must have progressive disease defined by RECIST criteria or defined by the Prostate Cancer
Clinical Trials Working Group II (Scher et al. 2008).

B. Subjects w/no measurable disease:

PSA only disease must have an elevated PSA as defined by Consensus Criteria Prostate
Cancer Clinical Trials Working Group II (Scher et al. 2008). PSA must indicate progressive
disease defined as rising PSA values, at least 7 days apart, >2 ng/mL in the 28 days prior
to randomization.

C. Subjects w/bone involvement:

New disease on bone scan as defined by Consensus Criteria Prostate Cancer Clinical Trials
Working Group II (Scher et al. 2008). 4. Subjects on stable dose of bisphosphonates
showing subsequent tumor progression may continue on this medication; however, subjects
are not allowed to initiate bisphosphonate therapy w/in 28 days prior to starting study
treatment at Week 1 or at any time after that during the study, 5. Must be clinically
immunocompetent. Clinical immunocompetence assumed unless subject has been diagnosed as
immunosuppressed, is receiving immunosuppressive chemotherapy for oncology disorders, or
is receiving immunosuppressive therapy following transplant, in which case they will be

6. Subject free of clinically apparent/active autoimmune disease (no prior confirmed
diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis,
Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, & Rheumatoid Arthritis).

7. Subject has adequate bone marrow function defined by Absolute Lymphocyte Count (ALC) ≥
500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.

8. Subject has peripheral neuropathy grade ≤1. 9. Subject has ECOG status of 0 or 1. 10.
Minimum life expectancy ≥6 months. 11. Progressive disease (as defined above) must be
documented after discontinuation of the hormonal and anti-androgen therapy.

12. Subject continues to stay on medical treatment such as LHRH agonists or LHRH
antagonists to maintain testosterone value of <50ng/dL.


1. Subject has received prior chemotherapy for prostate cancer at any time. Subject has
received chemotherapy for any other reason within five years of screening.

2. Subject is receiving any other hormonal therapy, including any dose of Megestrol
Acetate, Finasteride, any herbal product known to decrease PSA levels (e.g., Saw
Palmetto & PC-SPES), or any systemic corticosteroid must discontinue agent for at
least 4 weeks prior to the anticipated Week 1 visit. LHRH agonists or LHRH
antagonists do not need to be discontinued.

3. Subject has started bisphosphonate or denosumab therapy less than 28 days before the
anticipated Week 1 visit.

4. Subject is using supplements or complementary medicines/botanicals. Subjects should
review label w/their doctor prior to enrolment. Exceptions to this exclusion:

- Conventional multivitamin supplements

- Selenium

- Lycopene

- Soy supplements

- Vitamin E

- Fish oil supplements

- Vitamin D

- Glucosamine supplements

- Age-related eye disease vitamins

- Ginkgo biloba

5. Subject has had major surgery or radiation therapy completed <4 weeks prior to

6. Corticosteroids are not permitted except for (a) nasal sprays and inhalers, (b)
orally prescribed as replacement therapy in the case of adrenal insufficiency, (c)
oral or IV dexamethasone administration used acutely in combination with docetaxel,
(d) parenteral use on a single occasion, (e) low dose parenteral use for a maximum of
5 days and (f) acute and sporadic parenteral use for acute asthma.

7. Subject is known to test positive for HIV or hepatitis B or C.

8. Subject receiving concurrent chemotherapy, immunotherapy, radiotherapy or
investigational agents.

9. Subject has Platelet count >400,000/μL; Monocytes >80,000/μL; Haemoglobin <11g/dL.

10. Subject has cerebral metastases (known from previous investigations or clinically

11. Subject has serum testosterone >50ng/dL.

12. Subject has rheumatoid disease (asymptomatic subjects w/controlled & rarely flaring
rheumatoid arthritis are also excluded).

13. Subject exhibits evidence of symptomatic congestive heart failure, pulmonary embolus,
vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable
angina, myocardial infarction or active ischemia on ECG. If an ECG taken prior to
screening but within 28 days of the anticipated Week 1 visit is not available, an ECG
must be performed at screening.

14. Subject has uncontrolled severe hypertension >150/100mm Hg (if controlled
w/medication this is not an exclusion).

15. Subject is hypotensive.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Description:

To establish whether the incidence of progression-free survival (as defined by the absence of progression assessed by both RECIST and PCWG2 criteria) at week 37 in the TroVax® plus Docetaxel treatment arm is higher than the incidence in the Docetaxel alone treatment arm.

Outcome Time Frame:

Week 37

Safety Issue:


Principal Investigator

Anna C. Ferrari, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

New York University Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

August 2010

Completion Date:

March 2013

Related Keywords:

  • Hormone Refractory Prostate Cancer
  • cancer of prostate
  • cancer of the prostate
  • neoplasms prostate
  • neoplasms prostatic
  • prostate cancer
  • prostate neoplasms
  • prostatic cancer
  • prostate specific antigen
  • prostatic hyperplasia
  • Prostatic Neoplasms



Stanford University Medical Center Stanford, California  94305-5408
Rush University Medical Center Chicago, Illinois  60612-3824
New York University Cancer Institute New York, New York  10016
Charleston Hematology Oncology Associates Charleston, South Carolina  29403
Gabrail Cancer Center Research Canton, Ohio  44718
San Bernardino Urology San Bernardino, California  92404
GU Research Network Omaha, Nebraska  68130